Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In the liver, retatrutide has similar efficacy to naturally occurring glucagon in evoking glucose production
Karlsson, H
A transcriptomic atlas of aged human microglia
Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch
Retatrutide is the first triple-receptor agonist ever developed, activating GLP-1, GIP, and glucagon receptors simultaneously
Sources Nature Medicine: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial PubMed: Tirzepatide Once Weekly for the Treatment of Obesity Cleveland Clinic Journal of Medicine: Tirzepatide adds significant weight loss even after lifestyle changes MedicalNewsToday: How to Travel with Zepbound FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers Important Current Status Update : On March 19, 2025, the FDA ended enforcement discretion for compounded tirzepatide
US$ 24.13
US$ 28.34
US$ 22.65
US$ 29.42
US$ 28.02
US$ 27.61
US$ 29.41
